Contrasting Marker Therapeutics (NASDAQ:MRKR) and Integrated BioPharma (OTCMKTS:INBP)

Integrated BioPharma (OTCMKTS:INBP) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Volatility & Risk

Integrated BioPharma has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Integrated BioPharma and Marker Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated BioPharma	1.49%	4.04%	3.16%
Marker Therapeutics	-271.12%	-114.59%	-90.31%

Analyst Recommendations

This is a summary of recent ratings and price targets for Integrated BioPharma and Marker Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated BioPharma	0	0	0	0	0.00
Marker Therapeutics	1	0	1	2	3.00

Marker Therapeutics has a consensus price target of $10.25, indicating a potential upside of 895.15%. Given Marker Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Integrated BioPharma.

Insider & Institutional Ownership

25.3% of Integrated BioPharma shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 67.2% of Integrated BioPharma shares are owned by insiders. Comparatively, 7.8% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Integrated BioPharma and Marker Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated BioPharma	$54.35 million	0.18	$810,000.00	$0.02	15.50
Marker Therapeutics	$6.59 million	2.02	-$10.73 million	($1.37)	-0.75

Integrated BioPharma has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.

Summary

Integrated BioPharma beats Marker Therapeutics on 9 of the 15 factors compared between the two stocks.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.